ArticleInternational journal of clinical pharmacy2025
Real-world safety assessment of ublituximab: a pharmacovigilance analysis based on the FDA adverse event reporting system.
Article in International journal of clinical pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
introductionUblituximab, a novel glycoengineered murine/human type Ⅰ chimeric IgG1-class monoclonal antibody targeting a unique CD20 epitope, is approved for the management of relapsing forms of multiple sclerosis in adults. While the safety and efficacy of ublituximab have been evaluated in several randomized clinical trials, real-world pharmacovigilance data remain limited.
aimThis study aimed to evaluate the post-marketing adverse events (AEs) associated with ublituximab utilizing the FDA Adverse Event Reporting System (FAERS) database, thereby delineating the safety profile of ublituximab in the post-approval setting.
methodThe AE reports of ublituximab as the primary suspected drug from Q4 2022 to Q4 2024 were collected from the FAERS database. Disproportionality analysis, including the Reporting Odds Ratio, the Proportional Reporting Ratio, the Bayesian Confidence Propagation Neural Network, and the Multi-Item Gamma Poisson Shrinker, was performed to identify potential safety signals associated with ublituximab. Complementary analyses, comprising subgroup analysis, Weibull distribution, and sensitivity assessment, were conducted to characterize the ublituximab-associated AEs.
resultsA total of 1,190 reports encompassing 448 distinct AEs were collected. Known AEs that are consistent with the FDA label, such as infusion-related reactions (n = 591, ROR = 271.35, 95% CI 246.57-298.61) and infections (urinary tract infection: n = 28, ROR = 4.31, 95% CI 2.97-6.27; Respiratory tract infection: n = 8, ROR = 7.39, 95% CI 3.69-14.8), were reaffirmed, along with unexpected AEs like alopecia (n = 12, ROR = 2.06, 95% CI 1.17-3.64) and headache (n = 50, ROR = 2.55, 95% CI 1.93-3.38). The Weibull distribution characteristic of AEs is an early failure type, which indicates that vigilant monitoring in the initial treatment cycle is critical. Subgroup analyses revealed variations in the distribution across age and gender subgroups. Sensitivity analysis confirmed the consistency and robustness of the data.
conclusionThis study provided preliminary insights into the post-marketing safety profile of ublituximab by confirming its known AEs and investigating unexpected AEs. These findings contribute to evidence-based risk minimization strategies and pharmacovigilance activities for ublituximab in clinical practice.
Indexed as
Identifiers
41118058What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.